ImmuCell (NASDAQ:ICCC) Announces Earnings Results

ImmuCell (NASDAQ:ICCC) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.06) earnings per share for the quarter, Zacks reports. The business had revenue of $7.26 million during the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%.

ImmuCell Stock Performance

Shares of NASDAQ ICCC traded down $0.60 during mid-day trading on Wednesday, reaching $4.88. 66,622 shares of the company’s stock were exchanged, compared to its average volume of 9,077. The firm has a market capitalization of $38.16 million, a price-to-earnings ratio of -6.55 and a beta of 0.60. The firm has a 50-day moving average price of $5.16 and a two-hundred day moving average price of $5.03. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.73 and a quick ratio of 0.87. ImmuCell has a 52 week low of $4.34 and a 52 week high of $6.05.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.